Previous 10 | Next 10 |
home / stock / fh:cc / fh:cc news
VANCOUVER, BC / ACCESSWIRE / July 25, 2023 / The Power Play by The Market Herald has announced the release of new interviews with Etruscus Resources, Filament Health and Lancaster Resources discussing their latest news. The Power Play by The Market Herald provides investors with a quick snapsho...
FILAMENT HEALTH ANNOUNCES UPSIZING AND CLOSING OF $2,500,000 NON-BROKERED PRIVATE PLACEMENT FINANCING Canada NewsWire Financing led by psychedelic investment fund Negev Capital VANCOUVER, BC , July 24, 2023 /CNW/ - Filament Health Corp. (OTCQB: FL...
FILAMENT HEALTH CORP. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT UNIT OFFERING OF UP TO C$2,000,000 Canada NewsWire Financing led by premier psychedelics focused investment fund Negev Capital VANCOUVER, BC , July 19, 2023 /CNW/ - Filament Health Corp. (...
FILAMENT HEALTH CORP. TO LIST ON NASDAQ THROUGH BUSINESS COMBINATION WITH JUPITER ACQUISITION CORPORATION Canada NewsWire Business combination ascribes Filament US$176 million in equity value representing US$0.85 per Filament share and reflects a pro forma enterprise v...
FILAMENT HEALTH ANNOUNCES CHANGE OF AUDITOR Canada NewsWire VANCOUVER, BC , July 14, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development...
FILAMENT HEALTH TO SUPPLY PSILOCYBIN FOR RECIPIENTS OF THE CANADIAN INSTITUTES OF HEALTH RESEARCH PSILOCYBIN OPERATING GRANTS Canada NewsWire The CIHR is funding clinical trials through its Operating Grants for Psilocybin-assisted Psychotherapy for Mental Health and Substance ...
FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT WITH NEOLUMINA BIOSCIENCE INC. Canada NewsWire NeoLumina's license for Filament's botanical psilocybin drug candidate provides exclusive global right to clinical and commercial development for eating disorders VANC...
FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO Canada NewsWire Healthy subjects have been dosed with Filament's botanical psilocybin and psilocin drug candidates VANCOUVER, BC , May 30, ...
FILAMENT HEALTH ANNOUNCES FIRST EVER NAGOYA PROTOCOL-COMPLIANT SHIPMENT OF IBOGA FROM GABON Canada NewsWire The botanical raw material was shipped to Filament's Vancouver facility for analysis and development into ibogaine extract VANCOUVER, BC , May 17, ...
FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , May 12, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage n...
News, Short Squeeze, Breakout and More Instantly...
FILAMENT HEALTH CORP. Company Name:
FH:CC Stock Symbol:
AQNC Market:
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...
FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER Canada NewsWire VANCOUVER, BC , June 3, 2024 /CNW/ - Filament Health Corp. (OTCQB:...